Biogen (BIIB) Change in Acquisitions & Divestments (2009 - 2026)
Biogen (BIIB) recorded quarterly Change in Acquisitions & Divestments of $500000.0 in Q1 2026, up 101.49% quarter-over-quarter from -$33.6 million in Q4 2025.
Biogen (BIIB) Change in Acquisitions & Divestments (2009 - 2026) Analysis & Trends
Biogen's Change in Acquisitions & Divestments history runs 18 years deep, the most recent figure standing at $500000.0 for Q1 2026.
- In Q1 2026, Change in Acquisitions & Divestments changed N/A year-over-year to $500000.0; the TTM figure through Mar 2026 stood at $23.5 million (up 142.27% YoY), while the FY2025 annual figure was $23.0 million, changed N/A from the prior year.
- Change in Acquisitions & Divestments was $500000.0 for Q1 2026 at Biogen, up from -$33.6 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $5.7 billion in Q3 2023 to a low of -$96.7 million in Q4 2024.
- Historically, Change in Acquisitions & Divestments has averaged $791.1 million across 5 years, with a median of $231.6 million in 2023.
- The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments jumped 246.8% in 2023, then slumped 99.85% in 2024.
- A 5-year view of Change in Acquisitions & Divestments shows it stood at $566.3 million in 2022, then jumped by 906.29% to $5.7 billion in 2023, then sank by 101.7% to -$96.7 million in 2024, then jumped by 65.25% to -$33.6 million in 2025, then surged by 101.49% to $500000.0 in 2026.
- The last three Change in Acquisitions & Divestments figures came in at $500000.0 (Q1 2026), -$33.6 million (Q4 2025), and $56.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | -33.60 Mn |
| Dec 31, 2025 | -33.60 Mn |
| Sep 30, 2025 | 56.60 Mn |
| Sep 30, 2025 | 56.60 Mn |
| Dec 31, 2024 | -96.70 Mn |
| Dec 31, 2024 | -96.70 Mn |
| Sep 30, 2024 | 39.20 Mn |
| Sep 30, 2024 | 39.20 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 55.60 Mn |
| Mar 31, 2024 | 55.60 Mn |
| Sep 30, 2023 | 5.70 Bn |
| Sep 30, 2023 | 5.70 Bn |
| Jun 30, 2023 | 1.28 Bn |
| Jun 30, 2023 | 1.28 Bn |
| Mar 31, 2023 | 406.70 Mn |
| Mar 31, 2023 | 406.70 Mn |